Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
- 19 November 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 123 (3), 651-660
- https://doi.org/10.1007/s10549-009-0632-6
Abstract
Insulin receptor substrate-1 (IRS-1) is a cytoplasmic scaffolding protein that is phosphorylated by insulin-like growth factor-I receptor and recruits downstream effectors. Recent evidence suggests that IRS-1 has a nuclear localization and function. Here we investigated whether nuclear and cytoplasmic IRS-1 levels are associated with clinico-pathological characteristics and clinical outcome in breast cancer patients. Tissue microarrays from 1,097 patients with stage I–II breast cancer were stained by immunohistochemistry for IRS-1. Nuclear and cytoplasmic IRS-1 were scored separately according to the Allred score. Nuclear IRS-1 showed a positive association with estrogen receptor (ER) (r = 0.09, P = 0.003) and progesterone receptor (PR) (r = 0.08, P = 0.008) status and a negative correlation with lymph node involvement (r = −0.10, P = 0.001). Cytoplasmic IRS-1 did not correlate with ER or PR but showed a positive correlation with tumor size (r = 0.10, P = 0.001) and S-phase fraction (r = 0.16, P < 0.001). In univariate analysis, tamoxifen-treated patients with tumors showing positive nuclear IRS-1 had a better recurrence-free survival (RFS) (P = 0.009) and overall survival (OS) (P = 0.0007), while no association was shown between cytoplasmic IRS-1 and RFS or OS in the same group of patients. In multivariate analysis of patients receiving tamoxifen, negative nuclear IRS-1 showed a significantly reduced RFS (P = 0.046) and OS (P = 0.018). Combining both PR and nuclear IRS-1, tamoxifen-treated patients with PR+/IRS-1+ tumors had a better RFS (P = 0.0003) and OS (P < 0.0001) when compared with patients with PR−/IRS-1− tumors. In conclusion, nuclear IRS-1 may be a useful marker to predict tamoxifen response in patients with early breast cancer, particularly when assessed in combination with PR.Keywords
This publication has 32 references indexed in Scilit:
- Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistanceBreast Cancer Research and Treatment, 2007
- Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genesOncogene, 2007
- Expression of nuclear insulin receptor substrate 1 in breast cancerJournal of Clinical Pathology, 2007
- The estrogen receptor α:insulin receptor substrate 1 complex in breast cancer: structure–function relationshipsAnnals of Oncology, 2007
- Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor MetastasisMolecular and Cellular Biology, 2006
- RNAi‐mediated silencing of insulin receptor substrate 1 (IRS‐1) enhances tamoxifen‐induced cell death in MCF‐7 breast cancer cellsJournal of Cellular Biochemistry, 2006
- Nuclear insulin receptor substrate 1 interacts with estrogen receptor α at ERE promotersOncogene, 2004
- Nuclear Translocation of Insulin Receptor Substrate-1 by Oncogenes And Igf-IJournal of Biological Chemistry, 2002
- Estradiol Increases IRS-1 Gene Expression and Insulin Signaling in Breast Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer CellsPublished by Elsevier BV ,1998